Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29009947 | 0.91 | SMN1; SMN2 (0.43) | NPSR1FFAR1FFAR4SMN1; SMN2RXRG | |
| SCHEMBL8796401 | 0.86 | NPSR1 (0.48) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL4717045 | 0.83 | FFAR1 (0.49) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL23655932 | 0.80 | NPSR1 (0.55) | NPSR1FFAR1FFAR4POLBRXRG | |
| SCHEMBL23782788 | 0.79 | FFAR1 (0.46) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL1261294 | 0.79 | SMN1; SMN2 (0.54) | NPSR1FFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL27828902 | 0.78 | POLB (0.53) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL12070041 | 0.77 | POLB (0.51) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL3797596 | 0.76 | FFAR1 (0.47) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL31674242 | 0.76 | FFAR1 (0.47) | NPSR1FFAR1FFAR4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | NPSR1 12/4885FFAR1 192/4885FFAR4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.